Avidity Biosciences Inc
RNA36.517USD
+0.597+1.66%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
4.40BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Avidity Biosciences Inc Unternehmen
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.
Unternehmensinformationen
BörsenkürzelRNA
Name des UnternehmensAvidity Biosciences Inc
IPO-datumJun 12, 2020
CEOMs. Sarah Boyce
Anzahl der mitarbeiter391
WertpapierartOrdinary Share
GeschäftsjahresendeJun 12
Addresse10578 Science Center Drive
StadtSAN DIEGO
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl92121
Telefon18584017900
Websitehttps://www.aviditybiosciences.com/
BörsenkürzelRNA
IPO-datumJun 12, 2020
CEOMs. Sarah Boyce
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Sarah Boyce
Ms. Sarah Boyce
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
423.43K
+105.68%
Ms. Teresa Mccarthy
Ms. Teresa Mccarthy
Chief Human Resources Officer
Chief Human Resources Officer
98.09K
+0.99%
Mr. John B. Moriarty
Mr. John B. Moriarty
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
50.00K
+100.00%
Ms. Kathleen P. Gallagher
Ms. Kathleen P. Gallagher
Chief Program Officer
Chief Program Officer
49.64K
-1.80%
Ms. Tamar Thompson
Ms. Tamar Thompson
Independent Director
Independent Director
6.69K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
6.69K
--
Mr. Carsten Boess
Mr. Carsten Boess
Independent Director
Independent Director
6.69K
--
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Independent Director
Independent Director
6.69K
--
Dr. W. Michael Flanagan, Ph.D.
Dr. W. Michael Flanagan, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Eric B. Mosbrooker
Mr. Eric B. Mosbrooker
Chief Commercial Officer
Chief Commercial Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Sarah Boyce
Ms. Sarah Boyce
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
423.43K
+105.68%
Ms. Teresa Mccarthy
Ms. Teresa Mccarthy
Chief Human Resources Officer
Chief Human Resources Officer
98.09K
+0.99%
Mr. John B. Moriarty
Mr. John B. Moriarty
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
50.00K
+100.00%
Ms. Kathleen P. Gallagher
Ms. Kathleen P. Gallagher
Chief Program Officer
Chief Program Officer
49.64K
-1.80%
Ms. Tamar Thompson
Ms. Tamar Thompson
Independent Director
Independent Director
6.69K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
6.69K
--
Umsatzaufteilung
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
1.57M
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
12.69%
Janus Henderson Investors
9.48%
T. Rowe Price Associates, Inc.
9.30%
Wellington Management Company, LLP
8.03%
The Vanguard Group, Inc.
7.65%
Other
52.85%
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
12.69%
Janus Henderson Investors
9.48%
T. Rowe Price Associates, Inc.
9.30%
Wellington Management Company, LLP
8.03%
The Vanguard Group, Inc.
7.65%
Other
52.85%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
47.08%
Investment Advisor
46.95%
Hedge Fund
6.31%
Venture Capital
5.98%
Corporation
4.21%
Research Firm
2.59%
Private Equity
1.94%
Individual Investor
1.01%
Sovereign Wealth Fund
0.60%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
495
141.64M
117.51%
-2.91M
2025Q1
508
142.16M
117.97%
-7.67M
2024Q4
492
135.01M
112.33%
-12.86M
2024Q3
467
132.62M
112.76%
+3.34M
2024Q2
414
118.94M
111.18%
+14.23M
2024Q1
365
96.48M
102.78%
+1.47M
2023Q4
345
83.09M
112.13%
-13.56M
2023Q3
334
86.17M
118.19%
-15.24M
2023Q2
328
86.81M
124.27%
-3.56M
2023Q1
328
80.46M
115.95%
-5.12M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fidelity Management & Research Company LLC
15.29M
12.69%
-866.01K
-5.36%
Mar 31, 2025
Janus Henderson Investors
11.43M
9.48%
+4.37M
+62.01%
Mar 31, 2025
T. Rowe Price Associates, Inc.
11.21M
9.3%
+289.32K
+2.65%
Mar 31, 2025
Wellington Management Company, LLP
9.68M
8.03%
+1.58M
+19.47%
Mar 31, 2025
The Vanguard Group, Inc.
9.22M
7.65%
-188.71K
-2.01%
Mar 31, 2025
RTW Investments L.P.
8.75M
7.26%
+814.06K
+10.26%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.40M
6.96%
-22.20K
-0.26%
Mar 31, 2025
Avoro Capital Advisors LLC
7.63M
6.33%
+125.00K
+1.67%
Mar 31, 2025
RA Capital Management, LP
6.30M
5.23%
--
--
Mar 31, 2025
Bristol Myers Squibb
5.08M
4.21%
--
--
Sep 30, 2024
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Global X Genomics & Biotechnology ETF
3.64%
ALPS Medical Breakthroughs ETF
2.32%
Tema Neuroscience and Mental Health ETF
1.72%
SPDR S&P Biotech ETF
0.91%
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
Direxion Daily S&P Biotech Bull 3X Shares
0.52%
Invesco Dorsey Wright SmallCap Momentum ETF
0.5%
ProShares Ultra Nasdaq Biotechnology
0.38%
Invesco Nasdaq Biotechnology ETF
0.38%
iShares Biotechnology ETF
0.32%
Mehr Anzeigen
Global X Genomics & Biotechnology ETF
Anteil3.64%
ALPS Medical Breakthroughs ETF
Anteil2.32%
Tema Neuroscience and Mental Health ETF
Anteil1.72%
SPDR S&P Biotech ETF
Anteil0.91%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.8%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.52%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil0.5%
ProShares Ultra Nasdaq Biotechnology
Anteil0.38%
Invesco Nasdaq Biotechnology ETF
Anteil0.38%
iShares Biotechnology ETF
Anteil0.32%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
